Uric Acid Levels, Kidney Function, and Cardiovascular Mortality in US Adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002

Abstract

Background Chronic kidney disease (CKD) and hyperuricemia often coexist, and both conditions are increasing in prevalence in the United States. However, their shared role in cardiovascular risk remains highly debated. Study Design Cross-sectional and longitudinal. Setting & Participants Participants in the National Health and Nutrition Examination Survey (NHANES) from 1988 to 2002 (n = 10,956); data were linked to mortality data from the National Death Index through December 31st, 2006. Predictors Serum uric acid concentration, categorized as the sex-specific lowest (<25th), middle (25th–<75th), and highest (≥75th) percentiles; and kidney function assessed by estimated glomerular filtration rate (eGFR) based on the CKD-EPI (CKD Epidemiology Collaboration) creatinine–cystatin C equation, and urinary albumin-creatinine ratio (ACR) Outcomes Cardiovascular death and all-cause mortality. Results Uric acid levels were correlated with eGFRcr-cys (r = −0.29; p<0.001), and were only slightly correlated with ACR (r = 0.04; p<0.001). There were 2,203 deaths up until December 31st, 2006, of which 981 were due to cardiovascular causes. Overall, there was a U-shaped association between uric acid levels and cardiovascular mortality in both women and men, although the lowest risk of cardiovascular mortality occurred at a lower level of uric acid for women compared with men. There was an association between the highest quartile of uric acid and cardiovascular mortality even after adjustment for potential confounders (HR, 1.48; 95% CI, 1.13–1.96), although this association was attenuated after adjustment for ACR and eGFRcr-cys (HR, 1.25; 95% CI, 0.89–1.75). The pattern of association between uric acid levels and all-cause mortality was similar. Limitations GFR not measured; mediating events were not observed. Conclusions High uric acid is associated with cardiovascular and all-cause mortality, although this relationship was no longer statistically significant after accounting for kidney function.

High serum uric acid is associated with increased cardio-ankle vascular index (CAVI) in healthy Japanese subjects: A cross-sectional study

“…Additionally, the lowest risk of cardiovascular mortality occurred at lower SUA in females compared with males [30]. This finding is consistent with our results.…”

Allopurinol and Progression of CKD and Cardiovascular Events: Long-term Follow-up of a Randomized Clinical Trial

“…17,18 In addition to its beneficial effect in patients with kidney disease, treatment with allopurinol reduces cardiovascular risk regardless of previous coronary artery disease, diabetes, inflammation, age, sex, and baseline kidney function. In a recent epidemiologic study 19 of NHANES (National Health and Nutrition Examination Survey;1988-1994and 1999-2002 10,956 participants), a U-shaped association was observed between uric acid level and cardiovascular mortality in both women and men, although the lowest risk of cardiovascular mortality was recorded at a lower uric acid level for women than for men. The authors also observed an association between the highest quartile of uric acid level and cardiovascular mortality, even after adjustment for potential confounders (HR, 1.48; 95% CI, 1.13-1.96); however, this association was attenuated after adjustment for albumin-creatinine ratio and eGFR (HR, 1.25; 95% CI, 0.89-1.75).…”

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

“…Empagliflozin reduces uric acid, possibly as a result of the effect of increased glucose concentration on glucose transporter 9 in the basolateral membrane of the proximal tubule and resulting increased uricosuria (22,32). Serum uric acid has been associated with an increased risk of CV death (33), but evidence is limited regarding the CV benefits of reducing uric acid (34), especially within the normal range and/or to the small degree observed in the EMPA-REG OUTCOME trial.…”